

TABLE I
REPORTED DISEASES¹ - TEXAS, 2011-2020²

DISEASE	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
AMEBIASIS	44	126	123	147	190	206	189	183	148	112
AMEBIC CNS ³	-	-	3	0	3	3	1	1	1	0
ANAPLASMOSIS	-	-	4	2	1	3	3	0	1	2
ANCYLOSTOMIASIS (HOOKWORM) ⁴	-	-	8	10	16	NR ⁵	NR	NR	NR	NR
ANTHRAX	-	-	0	0	0	0	0	0	0	0
ASCARIASIS ⁴	7	14	19	75	56	NR	NR	NR	NR	NR
BABESIOSIS	-	-	2	0	1	1	1	1	NR	NR
BOTULISM, FOODBORNE	0	5	1	0	1	0	0	4	0	0
BOTULISM, INFANT ⁶	10	11	11	8	7	7	7	7	1	4
BOTULISM, OTHER	0	0	1	0	0	1	0	0	0	0
BOTULISM, WOUND	9	-	0	0	1	1	1	2	1	1
BRUCELLOSIS	17	44	18	26	43	23	15	11	18	11
CALIFORNIA SEROGROUP VIRUSES ^{7, 8}	-	0	1	0	0	0	0	0	3	0
CAMPYLOBACTERIOSIS	2,949	5,391	5,048	5,449	4,667	3,944 ⁹	2,589	2,640	2,390	1,741
CARBAPENEM-RESISTANT <i>ENTEROBACTERIACEAE</i> (CRE)	751	1,137	1,245	1,139	1,240	873	NA ¹⁰	NR	NR	NR
CHAGAS DISEASE	19	28	32	33	27	25	20	19	NR	NR
CHICKENPOX (VARICELLA)	348	1,291	972	1,146	1,341	1,491	1,647	1,874	2,410	2,558
CHIKUNGUNYA	-	19	7	15	20	55	114	NR	NR	NR
CHOLERA	0	0	0	0	0	0	0	0	1	1
CONTAMINATED SHARPS INJURY	NA	NA	NA	NA	NA ¹¹	1,137	1,292	1,447	1,263	NA
CRYPTOSPORIDIOSIS	365	1,244	987	1,157	735	740	416	412	302	504
CYCLOSPORIASIS	581	1,039	353	319	148	316	200	351	44	14
CYSTICERCOSIS	6	14	12	10	16	14	16	7	10	9
DENGUE	62	74	20	43	45	32	34	95	16	7
ECHINOCOCCOSIS ⁴	-	-	2	0	2	NR	NR	NR	NR	NR
EHRLICHIOSIS	8	9	9	17	15	8	12	8	4	4
EHRLICHIOSIS/ANAPLASMOSIS – UNDETERMINED	0	0	0	0	1	NR	NR	NR	NR	NR
ENCEPHALITIS, NONARBOVIRAL	NR	NR	NR	NR	NR	NR	NR	NR	31	17
<i>ESCHERICHIA COLI</i> , SHIGA TOXIN-PRODUCING (STEC)	513	1,324	1,363	1,131	1,015	610	612	606	499	486
FASCIOLIASIS ⁴	0	0	1	0	0	NR	NR	NR	NR	NR
<i>HAEMOPHILUS INFLUENZAE</i> , INVASIVE	206	452	464	403	317 ¹²	11	12	5	3	2
HANTAVIRUS INFECTION	0	0	1	0	0	0	0	0	0	0
HANTAVIRUS PULMONARY SYNDROME	0	0	0	2	0	2	5	1	0	0
HEMOLYTIC UREMIC SYNDROME	5	22	18	24	14	14	6	20	13	22
HEPATITIS A, ACUTE	223	160	88	129	139	147	123	109	134	138
HEPATITIS B, ACUTE	50	69	102	106	156	159	122	142	170	204
HEPATITIS B, PERINATAL ¹³	0	0	1	2	2	1	3	2	4	4
HEPATITIS C, ACUTE	38	85	76	56	40	48	47	28	44	37
HEPATITIS E, ACUTE ¹⁴	9	12	31	20	22	15	17	7	9	14
INFLUENZA, NOVEL A	0	0	0	1	0	0	0	0	0	0
INFLUENZA-ASSOCIATED PEDIATRIC MORTALITY ¹⁵	10	24	13	12	7	12	23	17	12	11
JAPANESE ENCEPHALITIS VIRUS ⁶	0	0	0	0	0	0	0	0	0	1
LEGIONELLOSIS	317	421	415	327	270	292	256	168	158	111
LEISHMANIASIS	-	10	15	8	13	6	12	11	6	4
LISTERIOSIS	33	65	54	42	34	41	19	28	28	51
LYME DISEASE	11	42	47	66	71	54	40	82	75	74
MALARIA	47	159	144	158	159	99	106	90	102	102
MEASLES	0	23	9	1	1	1	10	27	0	6
MENINGITIS, ASEPTIC	NR	NR	NR	NR	NR	NR	NR	NR	1,169	1,294
MENINGITIS, BACTERIAL/OTHER ¹⁶	NR	NR	NR	NR	NR	NR	NR	NR	387	422
MENINGOCOCCAL INFECTION ¹⁷	17	26	21	17	23	30	22	30	37	30
MULTIDRUG-RESISTANT <i>ACINETOBACTER</i> (MDR-A)	1,056	1,270	1,354	1,144	1,006	978	NA ¹⁰	NR	NR	NR
MUMPS	22	783	264	470	191	20	15	13	15	68
PARAGONIMIASIS ⁴	0	0	0	0	0	NR	NR	NR	NR	NR
PERTUSSIS	343	1,320	1,168	1,765	1,286	1,504	2,576	3,985	2,218	961
POLIOMYELITIS ¹⁸	0	0	0	0	0	0	0	1	0	0
PRION DISEASE ¹⁹	41	46	36	25	33	20	27	14	22	18
Q FEVER	5	19	22	20	19	13	12	20	12	19
RELAPSING FEVER, TICK-BORNE	NR	NR	NR	NR	NR	1	0	0	0	0
RICKETTSIOSIS, UNSPECIFIED ²⁰	5	19	12	9	13	4	NA ¹¹	NA ¹¹	NA ¹¹	NA ¹¹
RUBELLA	-	0	2	1	0	2	0	0	0	0
RUBELLA, CONGENITAL SYNDROME ²¹	0	0	0	2	0	0	0	0	0	0
SALMONELLOSIS	3,036	5,575	5,888	5,113	5,901	5,727	5,145	4,946	4,990	5,218
SHIGELLOSIS	1,385	4,042	1,357	1,522	4,386	5,623	2,743	2,386	1,926	2,539
SPOTTED FEVER RICKETTSIOSIS	12	23	76	106	87	61	94	83	77	52
ST. LOUIS ENCEPHALITIS VIRUS ⁷	-	0	0	0	0	0	4	1	3	0
STREPTOCOCCUS PNEUMONIAE, INVASIVE	840	1,983	2,029	1,798	1,737	1,693	1,562	1,715	1,535	1,603
STREPTOCOCCUS, GROUP A, INVASIVE	545	971	1,023	851	706	729	601	419	333	427

DISEASE	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
STREPTOCOCCUS, GROUP B, INVASIVE	1,402	2,124	2,016	1,929	1,761	1,703	1,356	1,050	1,020	903
TAENIASIS	-	-	1	1	2	6	1	0	1	1
TETANUS	-	-	1	1	2	2	4	2	3	2
TRICHINOSIS	0	0	0	0	4	4	2	0	1	2
TRICHURIASIS ⁴	0	-	6	12	21	NR	NR	NR	NR	NR
TULAREMIA	0	0	0	1	3	1	0	1	0	0
TYPHOID FEVER	10	36	29	27	37	24	20	13	29	26
TYPHUS, FLEA-BORNE (ENDEMIC, MURINE)	526	591	738	519	364	324	308	222	263	286
<i>VIBRIO PARAHAEMOLYTICUS</i>	12	39	43	30	23	22	17	22	16	29
<i>VIBRIO VULNIFICUS</i>	21	36	22	34	36	35	16	22	15	17
<i>VIBRIO</i> , OTHER/UNSPECIFIED	67	214	206	119	42	45	44	40	35	33
VIRAL HEMORRHAGIC FEVER ²²	0	0	0	0	0	0	3	0	0	0
VISA ²³	-	7	3	3	13	9	5	8	23	6
WEST NILE FEVER	21	8	38	48	118	79	126	70	1,024	7
WEST NILE NEUROINVASIVE DISEASE	101	24	108	87	252	196	253	113	844	20
YERSINIOSIS	117	230	35	46	58	44	26	35	22	18
ZIKA VIRUS DISEASE	0	-	4	55	315	8	NR	NR	NR	NR

Note: Per Emerging and Acute Infectious Disease Unit Data Suppression policy, beginning with data published after September 2021, conditions with statewide case counts of 1-4 and any fatalities counts of 1-9 are not provided (-).

¹ Diseases listed reflect those that were notifiable in Texas based on Texas Administrative Code and where cases were reported in the previous ten-year period. Counts are by calendar year. Case counts are presumed to be underestimates of true disease incidence due to incomplete reporting. Data in this table may not match tables in articles in this publication that were written prior to completion of data review for this report, or other previously published materials.

² Due to the extenuating circumstances arising from the COVID-19 Pandemic, a considerable decline in the reported number of cases was noted across many notifiable conditions by the Texas Department of State Health Services for 2020. Thus, the reported case counts and associated rates may not accurately reflect the incidence of disease in the population.

³ Amebic Central Nervous System (CNS) infections include primary amebic meningoencephalitis (PAM) caused by *Naegleria fowleri* and CNS infections caused by other amebae. Counts by organism and year: *Acanthamoeba healyi*: 1-2012, *Acanthamoeba* unspecified: 1-2016, 2-2018; *Balamuthia mandrillaris*: 1-2010, 1-2014, 1-2015, 1-2016, 1-2018; *Naegleria fowleri*: 1-2010, 1-2013, 2-2015, 1-2016, 1-2019, 3-2020.

⁴ Neglected tropical diseases reportable effective 2016 are ancylostomiasis (hookworm), ascariasis, echinococcosis, fascioliasis, paragonimiasis, and trichuriasis. Numbers previously published for 2016 for ancylostomiasis (hookworm), ascariasis, and trichuriasis have been corrected and include additional cases that were retrospectively identified.

⁵ Condition was not reportable (NR) in Texas.

⁶ Infant botulism cases are under 1 year of age by definition.

⁷ These arbovirus counts include both neuroinvasive and non-neuroinvasive cases.

⁸ California serogroup viruses includes California encephalitis, La Crosse, Jamestown Canyon, Keystone, snowshoe hare, and trivittatus viruses.

⁹ The count of Campylobacteriosis cases from 2015 was revised from previous data tables.

¹⁰ Data is not available (NA) for the whole year. MDR-A and CRE were not officially reportable until April 21st, 2014.

¹¹ Data is not available (NA) due to changes in case classification or surveillance practices.

¹² Effective in 2016, *Haemophilus influenzae* type b infection, invasive was expanded to all invasive *Haemophilus influenzae* regardless of type.

¹³ Perinatal hepatitis B cases are defined as infants >1 month through 24 months of age born in the US to HBsAg positive mothers.

¹⁴ Through 2010 only confirmed cases of acute hepatitis E are included. Beginning in 2011 a probable case definition was added and subsequent counts include both confirmed and probable cases.

¹⁵ Influenza-associated pediatric mortality cases are under 18 years of age by definition.

¹⁶ Meningitis, bacterial/other includes all cases of meningitis due to bacterial, fungal, and parasitic infectious agents. It includes cases that are also counted under specific etiologic agents such as *Haemophilus influenzae* serotype b, *Neisseria meningitidis*, Group A *Streptococcus*, Group B *Streptococcus*, *Streptococcus pneumoniae* and *Listeria monocytogenes*.

¹⁷ Includes all cases of invasive *Neisseria meningitidis* including cases of meningitis, septicemia, and joint infections.

¹⁸ The last reported case of wild-strain paralytic poliomyelitis occurred in Texas in 1977 and in the US in 1979. The last Texas case of vaccine-associated paralytic poliomyelitis (VAPP) acquired in the US occurred in 1999. The use of oral polio vaccine (OPV) was discontinued in the US in 2000. The 2013 case is travel-associated VAPP.

¹⁹ Effective in 2016, Creutzfeldt-Jakob disease was expanded to include all human prion disease.

²⁰ Rickettsia, unspecified replaced "dual reporting" in typhus/spotted fever cases in 2015. It was added to the Epi Case Criteria Guide in 2016 and defined as clinically compatible cases with serological evidence of elevated IgG or IgM antibody reactive with spotted fever and typhus group antigens by IFA that cannot be classified as either flea-borne typhus or spotted fever group rickettsioses.

²¹ Congenital rubella cases are under 1 year of age by definition.

²² This category includes exotic conditions such as Lassa fever, Marburg, and Ebola. Dengue and Hantavirus would be reported only under their respective conditions. In 2014 there were 3 cases of Ebola virus with onset in Texas, one case imported from Liberia and 2 nurses with secondary transmission from the imported case.

²³ Vancomycin-intermediate resistant *Staphylococcus aureus* (VISA)--*Staphylococcus aureus* with a vancomycin minimum inhibitory concentration (MIC) of 4 µg/mL through 8 µg/mL.